Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Unicycive Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +1 vs. Q1 2024
- Shares held
- 19.0M
- −2.25M (−10.6%) vs. Q1 2024
- Total value
- $9.52M
- −$22.1M (−69.9%) vs. Q1 2024
- New holders
- 5
- 6 more added
- Sold out
- 4
- 7 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 3,470,152 | $1.74M | 0.16% | 00.0% | Unchanged |
| Logos Global Management LP | 3,469,927 | $1.74M | 0.20% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 2,820,358 | $1.41M | 0.14% | −515,228−15.4% | Reduced |
| Ra Capital Management, L.P. | 2,632,200 | $1.32M | 0.02% | −838,488−24.2% | Reduced |
| BVF Inc | 2,200,000 | $1.10M | 0.03% | −1,411,601−39.1% | Reduced |
| Rosalind Advisors, Inc. | 1,571,200 | $787.3K | 0.62% | −308,446−16.4% | Reduced |
| Vanguard Group Inc | 1,138,220 | $570.4K | 0.00% | +798,360+234.9% | Added |
| Monashee Investment Management LLC | 1,000,000 | $501.1K | 0.06% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 285,738 | $143.2K | 0.00% | +32,545+12.9% | Added |
| Goldman Sachs Group Inc | 93,352 | $46.8K | 0.00% | +130.0% | Added |
| LPL Financial LLC | 85,000 | $42.6K | 0.00% | +85,000 | New |
| BlackRock Inc. | 51,837 | $26.0K | 0.00% | +51,837 | New |
| State Street Corp | 43,936 | $22.0K | 0.00% | +8,900+25.4% | Added |
| Renaissance Technologies LLC | 33,200 | $16.6K | 0.00% | −59,660−64.2% | Reduced |
| Northern Trust Corp | 23,998 | $12.0K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 18,800 | $9.42K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 18,485 | $9.26K | 0.00% | +10,807+140.8% | Added |
| Tandem Capital Management Corp | 15,500 | $7.08K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 11,094 | $6.00K | 0.00% | −14,988−57.5% | Reduced |
| Scientech Research LLC | 10,969 | $5.50K | 0.00% | +10,969 | New |
| Redwood Wealth Management Group, LLC | 3,000 | $1.50K | 0.00% | +3,000 | New |
| Bank of America Corp | 223 | $112 | 0.00% | +223 | New |
| JPMorgan Chase & Co | 70 | $35 | 0.00% | +23+48.9% | Added |
| UBS Group AG | 1 | $1 | 0.00% | −4,386−100.0% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −69,395−100.0% | Sold out |
| Ground Swell Capital, LLC | 0 | $0 | 0.00% | −19,118−100.0% | Sold out |
| Integrated Wealth Concepts LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −196−100.0% | Sold out |